Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04708145 · ClinicalTrials.gov registry record · Phase 4
Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
A Phase 4 study, sponsored by Greater Houston Retina Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
NCT04708145 is a Phase 4 study that has completed, run by Greater Houston Retina Research. The registered enrollment target is 41 participants.
The verdict
NCT04708145, a Phase 4 study, has completed, sponsored by Greater Houston Retina Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
Study Summary
The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, among subjects who completed the 2-year PANORAMA trial (VGFTe-OD-1411) and were treated in a clinical setting prior to joining the VOYAGE study.
Interventions
- DRUG Aflibercept Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04708145
The ClinicalTrials.gov registry entry for NCT04708145 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Greater Houston Retina Research, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aflibercept Injection is the first listed.
NCT04708145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04708145 about?
NCT04708145 is a clinical study titled "Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial". The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, among subjects who completed the 2-year PANORAMA trial (VGFTe-OD-1411) and were treated in a clinical setting prior to joining the VOYAGE study.
What is the current status of trial NCT04708145?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2021-06-01. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT04708145?
The interventions under investigation include: Aflibercept Injection (DRUG).
Who is sponsoring clinical trial NCT04708145?
This trial is sponsored by Greater Houston Retina Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.